| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
12 analysts have shared their evaluations of IQVIA Hldgs (NYSE:IQV) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 7 | 3 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 2 | 4 | 3 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Analysts have set 12-month price targets for IQVIA Hldgs, revealing an average target of $266.75, a high estimate of $300.00, and a low estimate of $230.00. This current average reflects an increase of 2.27% from the previous average price target of $260.82.
The perception of IQVIA Hldgs by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Sean Dodge | RBC Capital | Announces | Outperform | $275.00 | - |
| Anne Samuel | JP Morgan | Raises | Overweight | $288.00 | $260.00 |
| David Windley | Jefferies | Lowers | Hold | $242.00 | $266.00 |
| Tejas Savant | Morgan Stanley | Raises | Overweight | $280.00 | $270.00 |
| Dan Brennan | UBS | Raises | Buy | $300.00 | $295.00 |
| Jailendra Singh | Truist Securities | Raises | Buy | $300.00 | $292.00 |
| Elizabeth Anderson | Evercore ISI Group | Raises | Outperform | $270.00 | $230.00 |
| Luke Sergott | Barclays | Raises | Overweight | $275.00 | $255.00 |
| Eric Coldwell | Baird | Raises | Neutral | $251.00 | $235.00 |
| Eric Coldwell | Baird | Lowers | Neutral | $235.00 | $241.00 |
| Elizabeth Anderson | Evercore ISI Group | Lowers | Outperform | $230.00 | $250.00 |
| Luke Sergott | Barclays | Lowers | Overweight | $255.00 | $275.00 |
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of IQVIA Hldgs's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on IQVIA Hldgs analyst ratings.
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: IQVIA Hldgs's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 2.31%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: IQVIA Hldgs's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 9.52%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 5.56%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): IQVIA Hldgs's ROA stands out, surpassing industry averages. With an impressive ROA of 1.37%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 2.0, IQVIA Hldgs faces challenges in effectively managing its debt levels, indicating potential financial strain.
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: IQV
